ROBENGATOPE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROBENGATOPE is an injectable pharmaceutical product approved in 1971 by Bracco with an unknown mechanism of action and indication profile. The drug's precise therapeutic target and clinical use cannot be determined from available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team downsizing or transition planning initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for ROBENGATOPE roles, reflecting LOE stage dynamics. Career prospects are limited to portfolio transition, lifecycle extension, or divestiture support functions.
Commercial Operations ManagerPortfolio Analyst
Worked on ROBENGATOPE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.